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Sickle cell anemia causes a distinct pattern of glomerular
dysfunction
ANTONIO GUASCH, MILLICENT CUA, WEI You, and WILLIAM E. MITCH
Renal Division, Department of Medicine, Emoiy University School of Medicine, Atlanta, Georgia, USA
Sickle cell anemia causes a distinct pattern of glomerular dysfunction.
We characterized glomerular function in adults with sickle cell anemia
(SSA): 12 with normal renal function (SSA-controls), and 15 with renal
insufficiency (SSA-CRF). GFR was similar in SSA-controls and healthy-
controls, however, renal plasma flow was increased in SSA-controls. In
SSA-CRF, the albumin and IgG excretion rates were enhanced. The
fractional clearances of all dextran sizes (26 to 64 A) were significantly
increased in both SSA-controls and SSA-CRF versus healthy-controls. In
SSA-CRF, the fractional clearance of dextrans >58 A was enhanced.
Analysis with an "isoporous+shunt" model revealed an increase in the
mean restrictive pore radius (ro) by 5 A in SSA-controls and SSA-CRF,
versus healthy-controls. In SSA-CRF, the total number of membrane
pores was reduced > 70%, and the shunt parameter increased twofold.
We conclude that SSA patients have a distinct pattern of glomerular
dysfunction with generalized increased permeability to dextrans, resulting
from an increase in pore radius. When CRF develops, the total number of
membrane pores is reduced, and a size-selectivity defect occurs. The
changes in dextran permeability cannot be attributed to purely hemody-
namic changes (increased RPF or low filtration fraction), or to known
modulators of membrane porosity. These findings suggest that unique
mechanism(s) are implicated in the pathogenesis of sickle glomerulopa-
thy.
Sickle cell anemia (SSA) can cause hematuria, an inability to
concentrate the urine, tubular defects and papillary necrosis
[1—4]. Several investigators have reported that a subset of patients
will develop a glomerulopathy, characterized by proteinuria and
progressive renal insufficiency, leading to ESRD [5—7]. While
certain tubular defects are almost universal in adults [8], the
prevalence of renal failure in adults with SSA [serum creatinine >
4 mg/dl, (352 /.IM/liter)] is estimated to be only 4% [7]. In a
retrospective analysis of 342 SSA patients treated at the Georgia
NIH Comprehensive Sickle Cell Center, we found 21(6%) with a
serum crcatinine > 1.4 mg/dl (123 fLM/liter, unpublished observa-
tions). However, we believe this number is likely to be an
underestimation of the prevalence of renal insufficiency, because
serum creatinine is an insensitive index of renal failure in SSA [a
serum creatinine > 1.4 mgldl (123 j.LM/liter) corresponds to a
GFR < 30 to 40 ml/min/1.73 m21 [9]. Thus, estimating renal
insufficiency from the prevalence of "abnormal" serum creatinine
values is intrinsically flawed.
We also found that macroalbuminuria is a more sensitive
marker of glomerular injury than serum creatinine [9]. Although
an accurate prevalence of albuminuria in SSA is not known,
limited observations suggest that albuminuria could be present in
as many as 40% of SSA patients [10]. These observations suggest
that glomerular involvement in SSA may be much more prevalent
than suspected, and since more SSA patients are living into their
fourth and fifth decade [11], glomerular disease in SSA may
become more important clinically.
Regarding the pathogenesis of the glomerular involvement in
SSA, glomerular dysfunction is initially characterized by hyperfil-
tration and hyperperfusion, with a low filtration fraction [12].
Later, the GFR is usually normal despite the persistence of a high
renal blood flow [13]. We found that the earliest clinical indication
of glomerular injury is an increase in the glomerular permselec-
tivity to proteins (albumin and IgG), occurring even when the
GFR is still in the normal range. This is accompanied by a
reduction in the ultrafiltration coefficient. When renal insuffi-
ciency occurs, there is a further decline in K1, accompanied by a
parallel loss of glomerular permselectivity to proteins, suggestive
of glomerular capillary wall injury [9].
Renal histology in patients with SSA without clinical renal
dysfunction is remarkable for glomerular hypertrophy and open,
dilated glomerular capillary loops [14]. Recently, Falk et al
described the glomerular histopathology in 10 proteinuric patients
with SSA and mild renal insufficiency [6]. They noted glomerular
hypertrophy and prominent segmental and global glomeruloscle-
rosis; immunofluorescence was negative. The findings of early
hyperfiltration and hyperperfusion accompanied by glomerular
hypertrophy, with later changes that include proteinuria, and
segmental and global glomerular sclerosis are compatible with a
hemodynamically-mediated pattern of glomerular injury.
Our purpose was to characterize glomerular hemodynamics and
capillary wall function in adult SSA patients without glomerular
involvement to elucidate possible mechanisms of glomerular
injury. We also characterized glomerular dysfunction in SSA
patients with renal insufficiency to ascertain the mechanisms of
proteinuria and to determine whether the type of injury is
compatible with known patterns of glomerular injury.
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We contacted patients with and without renal disease (defined
by an abnormal serum creatinine or proteinuria) from adult
patients with SSA followed at the Georgia NIT-i Comprehensive
Sickle Cell Center. The study of their glomerular function was
826
Guasch et al: Glomerular capillaty wall function in SSA 827
approved by the Human Investigations Committee of Emory
University. Twenty-seven African-American patients (12 males)
consented to the study; 19 patients were homozygous for hemo-
globin S and 8 had hemoglobin SC. Their median age was 29 years
(range 18 to 65 years). We divided the patients into two groups
according to the results of the glomerular function studies (see
below). Twelve patients had normal GFR and albumin excretion
rate (AER, SSA-controls) and fifteen had renal insufficiency
(GFR < 80 ml/minll.73 m2, SSA-CRF). In the latter group, a
renal biopsy was available in 5 patients and demonstrated typical
findings of sickle cell glomerulopathy [61. In the remaining
subjects, other causes of renal insufficiency were excluded based
on clinical history, serology and ultrasonography. Non-steroidal
antiinflammatory drugs were discontinued in 2 patients at least
one week prior to renal function studies to avoid their confound-
ing effects on renal hemodynamics. When renal function was
evaluated, all patients had been pain-free for at least two weeks
and did not have macroscopic hematuria. Sixteen healthy volun-
teers (11 African-American, 4 Caucasian, I Hispanic) with a
similar age and gender distribution were recruited to provide
control values. These subjects had no anemia or history of kidney
disease, were normotensive and had a normal urinary dipstick test
for glucose, protein and blood.
Glomerular function studies
Subjects were admitted to the Emory University Clinical Re-
search Center or the Renal Unit of Grady Memorial Hospital to
measure differential solute renal clearances. Blood pressure was
determined in the sitting position, mean arterial pressure (MAP)
was calculated as the sum of the diastolic blood pressure plus of
the difference between systolic and diastolic pressure. An indwell-
ing catheter was inserted in each arm to infuse clearance markers
and to collect blood. After a blood sample was obtained to
measure hematocrit, creatinine, albumin and IgG concentrations
and to determine plasma oncotic pressure, a diuresis was estab-
lished with an oral water load (10 to 15 mI/kg), and maintained by
drinking a volume of water equivalent to that of the voided urine.
Priming doses of inulin (50 mg/kg), para-aminohippuric acid
(PAH, 12 mg/kg) and dextran 40 (130 mg/kg) were administered,
followed by an infusion to achieve constant serum levels of 20 and
1.5 mg/dl for inulin and PAH, respectively. Dextran was infused at
half the rate of inulin. After a 60-minute equilibration period, four
timed (30 to 40 mm) urine collections were obtained by sponta-
neous voiding, and blood samples were taken at the beginning and
end of each urine collection period.
GFR was calculated as the average of the four inulin clearance
periods, and RPF from the clearances of PAH, corrected for
tubular extraction. In healthy controls and SSA patients with
normal renal function, we used an extraction of PAH of 0.85,
based on direct measurements [15, 16]. In SSA-CRF patients the
EPAH had not been measured; therefore, we used a value of 0.70
based on measured EPAH in other glomerulopathic patients with
renal insufficiency [15, 171. Filtration fraction (FF) was calculated
as the ratio between GFR by RPF. Total renovascular resistance
was calculated as systemic mean arterial pressure divided by renal
blood flow. Fractional protein and dextran clearances were calcu-
lated by dividing the clearance of each macromolecule by that of
inulin.
Laboratory measurements
Inulin and PAH were determined by the resorcinol and Mar-
shall's methods, as described [18]. Plasma oncotic pressure was
measured by membrane osmometry (Wescor Oncometer, Logan,
UT, USA) and was assumed to be equivalent to afferent arteriolar
oncotic pressure (rA). Efferent oncotic pressure (irE) was calcu-
lated as:
= A/(' — FF) (Eq,1)
and glomerular capillary oncotic pressure as the arithmetic
mean of ITA and E [17]. Creatinine was measured using a
Beckman II Creatinine Analyzer, and serum albumin and IgG
concentrations by a turbidometric technique using specific anti-
bodies (Turbitime System; Behring Diagnostics, Somerville, NJ,
USA). Urinary albumin and IgG were measured by a radioimmu-
noassay (Diagnostic Products Co., Los Angeles, CA, USA) and an
ELISA technique [9], respectively. The selectivity index (SI) was
calculated as the fractional clearance of IgG divided by the
fractional clearance of albumin (both values were determined in
the same urine sample).
Dextran in deproteinized plasma [19] and urine samples were
separated into narrow (2 A) fractions by gel permeation chroma-
tography, using XK 16 Pharmacia columns (1.6 cm internal
diameter and 90 cm in length), packed with Sephacryl HR 300 gel
(Pharmacia Fine Chemicals, Uppsala, Sweden). The columns
were calibrated with 8 dextran standards (with molecular weights,
determined by light scattering analysis, ranging from 3,850 to
102,200 daltons; Pharmacia Fine Chemicals, Uppsala, Sweden);
2.8 ml fractions were eluted with a 0.3% NaC1 buffer at a flow rate
of 1 mI/mm at 4°C, and assayed for dextran by the anthrorte
method [18]. The molecular weight for the eluted dextran frac-
tions was calculated from the Kay, according to:
Kay = (Ye — Vo)/(Vt — Vo) (Eq. 2)
where Ve is the elution volume, Vo is the void volume, deter-
mined from the elution of blue dextran, and Vt is the total packed
column volume. The Kay for the 3,850 and 102,200 dalton
fractions were 0.67 and 0.15, respectively. The dextran Einstein
Stokes molecular radius (r) was calculated from the molecular
weights according to the equation:
= 0.333 )< (molecularwt)°3
Theoretical analysis
(Eq.3)
We computed the intrinsic glomerular membrane parameters
from the dextran sieving profile and a heteroporous model of the
glomcrular capillary wall ("isoporous+shunt") described by Deen
et at [20]. In this model, the glomerular filtration barrier is
assumed to he perforated by restrictive pores of identical radius
(ro), and a small percentage of the membrane is perforated by
very large pores that do not discriminate dextran on the basis of
size and behave as a "shunt pathway." The shunt pathway is
characterized by a parameter (wo) that approximates the percent..
age of filtrate passing through the shunt-like pores. According to
this model, the glomerular filtration barrier to water and un-
charged macromolecules is characterized by three parameters: ro,
wo, and the two-kidney ultrafiltration coefficient, T(. An addi-
tional derived parameter is the ratio of total effective pore area
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Table 1. Demographics and clinical parameters
SBP DBP
Age Gender Hb Hematocrit
years M/F SS/SC % mm Hg
MAP Sr
mg/dl BSA
Healthy controls 30 7/10 NA 39 1 116 3 75 2 89 3 0.8 0.1 1.86 0.06
SSA-controls 32 4/11 5/6 31 2 118 5 66 5 83 4 0.7 0.1 1.78 0.05a
SSA-CRF 34 7/8 15/1 20 1a 125 4 69 4 88 4 1.6 0.3a 1.61 J1J4ah
Abbreviations are: NA, not applicable; BSA, body surface area. Age is presented in median values.
up < 0.05 vs. healthy controls
b P < 0.05 vs. SSA controls
Table 2. Protein excretion
Serum albumin Serum IgG Oncotic AER IgGER
pressure —
g/dl mm Hg p.g/min
Fractional clearances ><iO-
—
Albumin IgG SI.
Healthy controls 4.7 0.1 1.3 0.1 26 1 5 1 1 1 0.1 0.1 0.1 0.1 1.1 0.3
SSA-controls 4.8 0.1 1.6 0.1 27 1 15 4 3 1 0.4 0.1' 0.2 0.la 0.8 0.2
SSA-CRF 3.8 0.3" 1.5 0.1 23 1h 973 2l9 188 l26 129 53 63 44uh 0.3 o.i'
S.f. is selectivity index.
a P < 0.05 vs. healthy controls
h P < 0.05 vs. SSA controls
where S' is the total restricive pore area. Thus, if ro and I are
relatively unchanged, changes in S'Il are proportional to changes
in the total number of restrictive pores [181. The fractional
clearance of an uncharged macromolecule (such as dextran) is a
function of RPF, 1A' zP, Kf and the membrane parameters ro and
wo. For a set of glomerular hemodynamic measurements and an
experimental dextran sieving curve, we computed ro and wo as the
membrane parameters that minimized the differences between
the observed and calculated dextran sieving curves [20]. We also
computed the contribution of the nonselective shunt to the
fractional clearance of a macrolecule, from the fraction of filtrate
volume passing through the shunt [20]. This parameter ()
assumes no tubular reabsorption and provides an estimate of the
contribution of a size-selective defect to the proteinuria [21].
The rate of glomerular filtration is governed by the relationship
between ultrafiltration coefficient and net ultrafiltration pressure
according to:
GFR = Kf X 'UF Kf X (P
Kf = S x k
in animal studies [23, 24] and indirect evidence from studies of
adult humans [25, 26], a physiologic range for P in humans has
been estimated between 35 to 40 mm Hg. Thus, we computed Kf
at a zP of 40 mm Hg in all patients and controls. Moreover, since
SSA patients tend to have a lower systemic blood pressure [27],
while animal models of CRF are almost invariably associated with
intraglomerular hypertension [28—30], we also computed mem-
brane parameters in SSA patients at a zsP of 35 and 45.
Statistical analysis
Results are expressed, unless otherwise indicated, as mean
SEM. Rates of protein excretion and fractional protein clearances
were log-transformed to approximate a normal distribution, prior
to statistical analysis. Comparisons among the groups were per-
formed with an ANOVA, using Scheffé's correction. The corre-
lation between parameters was assessed by linear regression
analysis. Values are considered significant when P < 0.05.
Results
Clinical information is summarized in Table 1. Anemia was
more severe in the SSA-CRF group than in SSA-controls. In
SSA-controls, albumin and fgG excretion rates tended to be
higher than in healthy individuals, and were statistically different
when expressed as fractional clearances (Table 2). In the SSA-
CRF group, the mean albumin and IgG excretion rates were both
increased by about 60-fold as compared to SSA-controls (P <
0.05, Table 2), despite a lower GFR. Serum albumin was signifi-
cantly reduced, reflecting worsening proteinuria, and plasma
(Eq. 6) oncotic pressure tended to be lower in the SSA-CRF group thanin SSA-controls.
The absolute values for GFR were almost identical in the
healthy and SSA-control groups (108 7 vs. 106 6 mI/mm,
respectively), but when corrected for body surface area, GFR
tended to he higher in SSA control patients (Table 3). Renal
plasma flow was markedly increased in SSA-controls compared to
healthy controls (P < 0.05); after correcting for anemia, renal
and pore length (S'Il), which is related to the apparent total
number of restrictive pores (N), according to:
N = S'/ir ro2 (Eq. 4)
(Eq.5)
where K is the two-kidney ultrafiltration coefficient and UF is the
net ultrafiltration pressure (the difference between the transglo-
merular capillary hydrostatic pressure (P) and mean glomerular
oncotic pressure, sir). In turn,
where S is the total capillary surface available for filtration and k
is the intrinsic hydraulic membrane conductivity.
A mathematical model for the filtration of water was used to
compute Kf from values of GFR, RPF, A and zP [22]. Three of
these variables (GFR, RPF and IrA) were measured, the fourth,
P, has not been measured in humans. Based on micropuncture
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Table 3. Glomerular function
GFR RPF RBF
RVR
mm Hg/(ml/min/1. 73 m) FF
GC oncotic
pressure
mm Hg
Kf
unitsmI/mm/i. 73
Healthy controls 98 4 498 26 800 45 0.19 0.01 0.20 0.01 30 1 16 2
SSA-controls 108 7 699 66 997 77 0.13 0.Ola 0.16 0.01 28 1 12 I
SSA-CRF 41 5b 356 56at, 451 76' 0.37 007ab 0.13 001ah 25 2 4 jb
Abbreviations are: RVR, renovascular resistance; GC, glomerular capillary, Kf units, (ml/min)*mm Hg*1.73 m2.
aP < 0.05 vs healthy controls
blood flow also tended to be higher in SSA-controls than in
healthy subjects. Renal vasodilation was present in SSA-controls,
as indicated by a lower total renovascular resistance than in
healthy controls (Table 3). As shown in Figure 1, the ratio
between GFR and RPF (the filtration fraction) was lower, on
average, in SSA patients than in healthy controls. However, the
filtration fraction was more severely depressed in the renal failure
group than in SSA-controls, suggesting that other mechanism(s)
must account for the hypofiltration in the CRF group. Since the
average glomerular capillary oncotic pressure (the force opposing
the formation of filtrate) was reduced in SSA-CRF patients
(Table 3), there must be a reduction in the ultrafiltration coeffi-
cient to account for the hypofiltration (Eq. 5). In fact, the
estimated Kf was reduced by 2/3 in the SSA-CRF group as
compared to SSA-controls (P < 0.05). Note that the computed
reduction in K was present when a wide range (35 to 45 mm Hg)
of estimated intraglomerular pressures was used to calculate Kf
(Table 4).
In patients with SSA and normal renal function, the fractional
clearances for all dextrans (26 to 64 A) were significantly in-
creased compared to corresponding values in healthy controls
(Fig. 2A). In the group with renal insufficiency, the passage of
large dextrans (> 58 A) was selectively enhanced compared to
values from SSA-control patients or healthy controls (Fig. 2B).
Interestingly, the fractional clearance of smaller dextrans (<58 A)
did not differ between the SSA-CRF and SSA-control groups.
The computed membrane parameters are shown in Table 4.
The mean restrictive pore radius (ro) was increased by 5 A in SSA
patients as compared to healthy subjects (62 I vs. 57 1,
respectively, P < 0.001). This increase was present irrespective of
considered intraglomerular pressures (Table 4). In SSA-controls,
P
mmHg
Kf
units r0(A)
S'/l
Km
(00
XiO
Healthy controls
SSA-controls
SSA-CRF
40
40
40
16 212 1
4 1ab
57 162 P62 1
336 47
225 28
67 15ab
1.3 0.2
2.5 0.443 0.8'
SSA-controls
SSA-CRF
35
35
24 4
5 1
61 1
61 1
474 92
93 19
1.7 0.4
3.6 0.8
SSA-controls
SSA-CRF
45
45
7 1
3 1
62 1
62 1
134 11
52 14
3.2 0.5
5.1 0.9
the shunt parameter, wo, was not statistically different from that
of healthy controls, but in the proteinuric SSA-CRF group, wo
was increased almost twofold compared to SSA-control patients.
In contrast, the restrictive pore radius, ro, was not different in
SSA-CRF from that of SSA-controls. Similarly, the computed
membrane paramteres in the SSA-CRF group were not signifi-
cantly affected by assuming that EPAH was the same in SSA-CRF
as in SSA-control patients (data not shown). Thus, the reduced Kf
in the SSA-CRF group, must be caused by a reduction in the total
number of membrane pores (S'/l). In fact, the computed S'/l was
approximately 70% lower, on average. If renal insufficiency were
accompanied by glomerular hypertension (such as .P = 45 mm
Hg), then I( and S'/l would be reduced by 75% and 77%,
respectively (Table 4).
The relationship between two of the membrane parameters, S '/1
and wo, (Fig. 3) suggests that when the total number of pores
(S'/l) is reduced, the prominence of the shunt pathway increases
(r —0.75, P < 0.001). Pathophysiologically, progressive glomer-
ular capillary wall injury causing a loss of restrictive pores and a
relative abundance of shunt-like pores could account for this
relationship.
The albumin and IgG excretion rates were strongly correlated
(r = 0.86, P < 0.001) and the absolute AER exceeded the
excretion rate of IgG in all instances (data not shown). Likewise,
there was a strong correlation between the fractional protein
clearances (Fig. 4). While the ratio between the fractional IgU
and albumin clearances or selectivity index (SI) was close to 1 in
both healthy and SSA-controls, the corresponding value in the
SSA-CRF group was 0.3 (Table 2 and Fig. 4).
To determine whether the shunt pathway could account for the
observed fractional protein clearances, we calculated the hypo-
thetical fractional clearance of a non-reabsorbable macromole-
cule attributable to the shunt pathway (O). This quantity slightly
exceeds wo, because the concentration of the macromolecule
I
U-
250
200
150
100
50
0
0
0 0 0
o 0000 0&0 0 0
£ £ £
a
Table 4. Membrane parameters
0 250 500 750 1000 1250 Kf units are (ml/min)*mm Hg*1.73 m2.
a P < 0.05 vs. healthy controls
RPF, mi/rn/n/i. 73
hP < 0.05 vs. SSA controls
Fig. 1. Relationship between GFR and RPF in healthy controls (open
circles), SSA-controls (stippled circles) and SSA-CRF (solid triangles).
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Fig. 3. Relationship between two of the membrane parameters, pore density
(S/I) and prominence of the shunt pathway (wo), r = —0.75, P <0.001. The
symbols are the same as in Figure 1.
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Fig. 2. Dextran sieving profiles in SSA-controls versus healthy individuals(A) and in SSA-CRF and SSA-controls (B). < 0.05. Symbols are the
same as in Figure 1.
increases along the glomerular capillaries as water is removed by
glomerular filtration. As shown in Figure 5, fl exceeded the
observed fractional clearances of albumin and IgG in proteinuric
SSA patients with renal insufficiency, indicating that a defect in
size-selectivity could account for the observed protcinuria.
Discussion
We have found that adult SSA patients without clinical glomer-
ular disease have renal vasodilation (low total renovascular resis-
tance), a disproportionate increase in renal plasma flow, a ten-
dency towards a higher GFR, and a decreased filtration fraction.
More significantly, the fractional clearances for all dextrans
studied (26 to 64 A) are enhanced compared to healthy controls.
These data coupled with analysis with hydrodynamic pore theory
and a heteroporous model of the filtration barrier indicate there
1000
100
10
0.1
0.01
0.01 0.1 1 10 100 1000
Fractional albumin clearance
Fig. 4. Correlation between the fractional clearances of albumin and IgG.
The solid line represents a ratio between the two fractional clearances (or
selectivity index, SI) of 1. Note that in the SSA-CRF group, all values fall
below the identity line.
is a distinct alteration in glomerular capillary wall pore structure
in SSA. The restrictive pores (ro) in SSA patients are markedly
increased in size as compared to healthy controls, and this could
explain the consistently higher fractional clearances of all dex-
trans. This increase in the restrictive pore size is present irrespec-
tive of a wide range of potential intraglomerular pressures con-
sidered (Table 4). Taken together, these results indicate that there
must be structural changes in the glomerular capillary wall that
account for the changes in pore size.
In SSA patients with renal insufficiency, GFR was reduced
proportionally less than RPF, resulting in a filtration fraction that
I 
I 
I 
I 
:t.
;i:
i 
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is even more depressed than in SSA-controls (Table 3). A low
filtration fraction, combined with a lower oncotic pressure in the
SSA-CRF group (Table 3) should reduce the average P0c even
more than in SSA-controls. Consequently, the net ultrafiltration
pressure (PUF) for any level of sP would be higher in SSA-CRF
patients than in SSA-eontrols. In short, the ultrafiltration coeffi-
cient must be depressed to account for the observed low GFR
(Eq. 5 and Table 4). This reduced ultrafiltration capacity is
present, but, at the same time the passage of large dextrans (>58
A) is enhanced (Fig. 2B). In contrast with other glomerular
diseases where the filtration of smaller dextrans (<50 A) is
subnormal L1 18, 31—33], the fractional clearances of the dcx-
trans <50 A in the SSA-CRF group are not different from those
of SSA-controls.
How do these changes in pore size and presumed structure
affect proteinuria? The fractional clearances of albumin (an
anionic protein) and IgG (a neutral protein) were closely corre-
lated (r = 0.85, P < 0.001), suggesting that a permselectivity
defect accounts for both types of proteinuria. From the dextran
sieving analysis, the prominence of the shunt pathway (wo) was
twofold higher in the SSA-CRF compared to SSA-controls. The
contribution of the size-selective defect to total proteinuria (the
calculated theta infinity, O, which assumes negligible tubular
reabsoprtion) indicates that the shunt pathway could account fully
for the observed degree of proteinuria (Fig. 5). On the other
hand, estimating size-selectivity defects from calculated mem-
brane pore sizes derived from dextran sieving has limitations.
First, dextran molecules have been shown to permeate synthetic
membranes of uniform pore size more readily than neutral
spheres of similar molecular weight, while more rigid polysaccha-
rides (such as Ficoll) yield a closer approximation of the behavior
predicted for solid spheres [34]. This finding has been confirmed
in the rat [35]. Second, the ratio between the calculated value for
O and the fractional albumin and IgG clearances is approximately
1000:1 for both control groups and 10:1 for SSA CRF patients
(Fig. 5). This means that 99.9% of filtered proteins would be
reabsorbed in control subjects, but such tubular reabsorptive
capacity greatly exceeds the value directly determined in nonpro-
teinuric rats [36]. A more likely explanation for the difference
between predicted and observed fractional protein clearances is
that the dextran technique overestimates the size-selective defect
by a similar order of magnitude in all patients. In fact, the
magnitude of the shunt parameter determined from Ficoll sieving
in vivo in the normal rat is an order of magnitude less than that
determined from dextran [35]. Thus, the contribution of the shunt
parameter to the filtration of proteins is probably less than we
calculated.
If a glomerular size-selective defect alone were present in SSA
patients with proteinuria, a similar fractional clearance for all
proteins should be present. However, the ratio between the
fractional IgG and albumin clearances (the selectivity index or SI)
is close to 1.0 in the control groups, but is only 0.3 in SSA-CRF
patients, implying that the permselectivity to IgG is 1/3 of that of
albumin. Although these data support a parallel, charge-selective
defect, in vitro tubular studies of protein reabsorption have
demonstrated that the reabsoption of neutral or cationic proteins
(such as IgG) is enhanced compared to that of anionic proteins
(such as albumin) [37]. Such differential protein reabsorption,
could also account for the difference in the SI we observed. In
summary, a size-selective defect is present in SSA-CRF patients
and could account for most of the observed proteinuria; any
influence of a coexistant, charge-selective defect to the observed
difference in SI will require studies of glomerular permselectivity
using charged polymers [21].
Our interpretation of membrane characteristics from the dcx-
tran sieving analysis plus the measurements of renal hemodynam-
ics indicates that SSA is associated with a shift in the mean
glomerular pore radius to a larger size even in the absence of
clinically detectable glomerular injury. In humans, a shift in pore
size distribution towards larger pores has been reported only in a
few circumstances, namely, new-onset diabetes [38] or when
angiotensin II levels are elevated because of hypertension [39] or
experimentally, after an infusion of angiotensin II [40]. However,
in these conditions the hemodynamic profile is different from the
one we found in SSA patients. In new-onset diabetes, there is
hyperfiltration and hyperperfusion, but systemic blood pressure
tends to be higher than in non-diabetic subjects [41], the filtration
fraction is increased [38], and indirect evidence suggests that P
is also increased [38]. In high angiotensin II states, systemic blood
pressure is markedly elevated, filtration fraction is high, and GFR
is depressed, which is associated with reduced RPF and Kf [39,
40].
Pregnancy and certain pathological conditions (such as the
transplanted kidney or solitary kidney after uninephrectomy) can
be associated with renal hemodynamic changes similar to those we
found in SSA. However, in these conditions, the dextran sieving
profile differs; the dextran sieving curve is depressed rather than
increased, as we found in SSA-eontrols [42, 43]. Thus, the
hemodynamic profile combined with the dextran sieving data do
not suggest a mechanism of injury similar to that described in
other hemodynamically-mediated glomerulopathies.
What are likely values of intraglomerular pressures? Unfortu-
nately, P cannot he measured in humans, but our analysis of
glomerular hemodynamics, coupled with the morphometric anal-
yses of glomerular size in SSA patients [14, 44] can provide
1000
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ci)0
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a)0
C
.2 10(ci
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0.1
0.01
SSA-controls SSA-CRF Healthy controls
Fig. 5. Bar diagram of the mean values of the fractional protein clearance
attributable to the shunt (O), and fractional albumin and IgG clearances, in
SSA -controls, SSA-CRF and healthy controls. O. exceeds fractional protein
clearances in all instances.
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insights into the range of possible intraglomerular pressures in
SSA patients without glomerular disease. For example, the renal
vasodilation that occurs in SSA could allow a higher percentage of
systemic arterial pressure to be transmitted to the glomerular
capillaries, resulting in an increased P. Based on our physiolog-
ical observations, this possibility seems highly unlikely. First, SSA
patients without renal failure have a lower MAP than their
healthy counterparts (6 mm Hg, on average, Table 1, [27]).
Second, if the zP in SSA-controls were 5 mm Hg higher than that
of healthy controls (such as 45 vs. 40 mm Hg, respectively), the Kf
would be significantly reduced in SSA-controls compared to
healthy individuals (7 vs. 16, respectively, Table 4). However,
non-glomerulopathic SSA patients have been shown to have
glomerular hypertrophy, with a glomerular tuft planar area that is
twice that of non-SSA subjects [14, 441. With hypertrophy, it
seems likely that S, the total capillary filtration surface area, is
increased in SSA-controls. Consequently, if SSA-controls had
intraglomerular hypertension, the intrinsic hydraulic membrane
conductivity, k, would have to be markedly lower than in healthy
individuals (Eq. 6). It seems unlikely that membrane hydraulic
conductivity would be selectively reduced in subjects who do not
have other manifestations of glomerular injury. Instead, it is more
likely that P is slightly lower in SSA-controls than in healthy
controls. A reduction in zP of 5 mm Hg in SSA-controls (35 vs. 40
mm Hg in healthy controls) would result in a computed Kf of 24
in SSA-controls versus 16 in healthy individuals (Table 4). This
lower iP would be compatible with the lower MAP and the state
of renal vasodilation observed in SSA-controls. The higher K
computed for SSA-controls could be explained by the increase in
capillary surface (S), (compatible with glomerular hypertrophy)
coupled with an unchanged hydraulic membrane conductivity (k).
What might cause these hemodynamic alterations? They are
reminiscent of the changes that would occur upon activation of
the nitric oxide system with a low systemic blood pressure, but
renal hyperperfusion, a low filtration fraction and a tendency to a
low tXP [45]. Evidence for activation of the nitric oxide system in
SSA includes increased excretion of NO2 and NO3 by transgenic
mice with sickle hemoglobin [46]. Unfortunately, further compar-
isons cannot be made because dextran sieving has not been
performed in these animals, nor in healthy individuals were the
nitric oxide system has been stimulated experimentally. Regard-
less, the hemodynamic changes associated with activation of the
nitric oxide system should theoretically yield a generalized depres-
sion rather than enhancement of dextran clearances as we ob-
served in SSA-controls. Thus, SSA is associated with a distinct
pattern of glomerular dsyfunction.
If the hemodynamic changes associated with SSA cannot
account for the changes in dextran sieving, there must be struc-
tural differences at the level of the capillary wall. Possibly, sickle
erythrocytes sticking to the endothelial layer [47] activate endo-
thelial cells to release cytokincs, growth factors [48, 49] or
prostanoids [50]. It is tempting to speculate that such alterations,
coupled with stretching of the capillaries from hypertrophy, could
change the porosity of the glomerular capillary wall and the pore
size. This formulation suggests that therapy directed solely at
reducing efferent arteriolar resistence (such as by administering
an ACE inhibitor) would not correct the underlying hemodynamic
abnormality we described in SSA-controls. However, it is also
possible that other properties of angiotensin IT (such as as a
growth factor) could cause or contribute to the structural abnor-
malities and blocking these effects of angiotensin II would prove
beneficial. Once glomerular injury has occurred, other mecha-
nisms, probably involving angiotensin II, could operate to pro-
mote further damage. At this stage, blocking angiotensin II
formation, by administering an ACE inhibitor, has been shown by
Falk et alto reduce proteinuria, without lowering systemic blood
pressure or GFR, suggesting that an intraglomerular effect ac-
counts for the antiproteinuric action [6].
In summary, SSA, in adults, causes hemodynamic changes
characterized by renal vasodilation, glomerular hyperperfusion,
and normal glomerular filtration rate. This hemodynamic profile
is associated with a unique change in dextran sieving curve, with
generalized enhancement of the fractional dextran clearances.
This suggests a novel mechanism by which glomerular pore size is
modulated. In SSA patients with renal insufficiency, hypofiltration
and proteinuria results from glomerular capillary wall injury, with
loss of restrictive membrane pores and an increase in the prom-
inence of the shunt pathway.
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